An Open Label, Dose Escalation, Phase 1 Study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second Generation Proteasome Inhibitor, in Adult patients with Relapsed and Refractory Multiple Myeloma
Closed to Enrollment
This is one of the first two studies of the capsule form of the experimental drug MLN9708, administered orally, in people with relapsed and refractory multiple myeloma.
MLN9708 is a type of drug called proteasome inhibitor. Proteasome inhibitors work by inhibiting proteins (known as proteasomes) that cells need to survive and multiply. Cancer cells are more susceptible to this effect than normal cells. Inhibiting these proteins (proteasomes) may help kill cancer cells.
The purpose of this study is to determine:
- The side effects and risks of MLN9708
- The highest dose of the study drug that can be given to patients with multiple myeloma without causing side effects and risks that are too severe
- How much MLN9708 is in your blood and how your body gets rid of the drug
- How MLN9708 affects the cancer cells and how they grow
Disease Status and/or Stage
Relapsed or Refractory Multiple Myeloma
- Men and women age 18 and older
- Multiple myeloma, relapsed following at least 2 lines of therapy
- Detailed eligibility reviewed when you contact the study team
- June Greenberg, RN
- (212) 746-2651
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
For general inquiries, or if you need assistance finding a study, please contact:
Subject Recruitment Manager
Tel: (646) 962-9340